💊 Codeine (Ascomp With Codeine)
An oral capsule combining butalbital (a barbiturate), aspirin (a nonsteroidal anti-inflammatory drug), caffeine (a methylxanthine), and codeine phosphate (an opioid agonist) for the management of the symptom complex of tension (or muscle contraction) headache when non-opioid analgesics and alternative treatments are inadequate. Because of the risks of addiction, abuse, misuse, overdose, and death, it is reserved for patients for whom alternative treatment options are ineffective, not tolerated, or otherwise inadequate.
In Arabic: بيوتالبيتال وأسبرين وكافيين وفوسفات كوديين✅ What it is used for
- Management of the symptom complex of tension (or muscle contraction) headache
- Reserved for use when non-opioid analgesics and alternative treatments are inadequate
🧪 Active ingredient
Butalbital is a barbiturate that is a GABA A receptor agonist and may inhibit excitatory AMPA receptors; aspirin is a nonsteroidal anti-inflammatory drug and a non-selective irreversible inhibitor of cyclooxygenases; caffeine is a methylxanthine and CNS stimulant; codeine phosphate is an opioid agonist relatively selective for the mu-opioid receptor but with a much weaker affinity than morphine.
🌿 Benefits
- May help manage the symptom complex of tension headache in appropriate patients
- Combines an opioid analgesic, an anti-inflammatory drug, and a CNS stimulant in one capsule
📝 How to use
- For oral administration only
- The dose is set by the doctor or pharmacist and must not be changed by the patient
- Use the lowest effective dosage for the shortest duration consistent with individual treatment goals
💊 Dosage forms
- Capsules: butalbital 50 mg, aspirin 325 mg, caffeine 40 mg, and codeine phosphate 30 mg
⚠️ Common side effects
- Nausea and/or abdominal pain
- Drowsiness
- Dizziness or lightheadedness
- Intoxicated feeling
🚨 Serious — seek medical help
- Addiction, abuse, and misuse
- Life-threatening respiratory depression
- Risks from concomitant use with benzodiazepines or other CNS depressants
- Neonatal opioid withdrawal syndrome
- Opioid-induced hyperalgesia and allodynia
- Adrenal insufficiency
- Severe hypotension
- Risks in patients with gastrointestinal conditions including peptic ulcer disease
- Increased risk of seizures in patients with seizure disorders
- Withdrawal
- Coagulation abnormalities and bleeding risks
- Reye's syndrome
- Serious skin reactions
- Allergy
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
⛔ Do not use if
- All children younger than 12 years of age
- Postoperative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity or intolerance to aspirin, caffeine, butalbital, or codeine
- Hemophilia
- Reye's syndrome
- Known allergy to nonsteroidal anti-inflammatory drugs (NSAIDs)
- Syndrome of asthma, rhinitis, and nasal polyps
❗ Warnings & precautions
- Contains codeine and is a Schedule III controlled substance
- Risk of addiction, abuse, and misuse at any dosage or duration
- Serious, life-threatening, or fatal respiratory depression, especially during initiation or following a dosage increase
- Accidental ingestion of even one dose, especially by children, can result in a fatal overdose
- Concomitant use with benzodiazepines, alcohol, or other CNS depressants may result in profound sedation, respiratory depression, coma, and death
- Assess each patient's risk before prescribing and reassess all patients regularly for addiction, abuse, and misuse
- Do not rapidly reduce or abruptly discontinue in a physically dependent patient
- Opioid-induced hyperalgesia and allodynia may occur
- Use caution in elderly, cachectic, or debilitated patients and in patients with chronic pulmonary disease
- Adrenal insufficiency and severe hypotension may occur
- Use caution in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness
- Fetal toxicity with NSAIDs including aspirin
🔄 Drug interactions
- CYP3A4 inhibitors such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir): may increase codeine and morphine levels, increase or prolong adverse reactions, and may cause potentially fatal respiratory depression
- CYP3A4 inducers: may result in decreased efficacy or onset of a withdrawal syndrome
- Monoamine oxidase inhibitors (MAOIs): contraindicated with or within the last 14 days
- Benzodiazepines and other CNS depressants including alcohol: may result in profound sedation, respiratory depression, coma, and death
🤰 Pregnancy
Use of opioid analgesics for an extended period of time during pregnancy may cause neonatal opioid withdrawal syndrome. Use of NSAIDs including aspirin can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Because of these risks, limit dose and duration of use between about 20 and 30 weeks of gestation, and avoid use at about 30 weeks of gestation and later in pregnancy.
🍼 Breastfeeding
Breastfeeding is not recommended.
🧒 Children
Contraindicated for all children younger than 12 years of age and for postoperative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. Safety and effectiveness in pediatric patients have not been established. Preparations containing aspirin should be kept out of the reach of children because of the risk of Reye's syndrome. Avoid use in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine unless the benefits outweigh the risks.
👴 Older adults
Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Dose selection should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. Respiratory depression is the chief risk for elderly patients treated with opioids; titrate the dosage slowly and frequently reevaluate for signs of CNS and respiratory depression.
🌡️ Storage
Store below 25°C (77°F) in a tight, light-resistant container. Protect from moisture. Store securely and dispose of properly.
🆘 Overdose
Acute overdose can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, hypoglycemia, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen with hypoxia. In case of overdose, priorities are the reestablishment of a patent and protected airway and institution of assisted or controlled ventilation if needed, with other supportive measures and administration of an opioid overdose reversal agent for clinically significant respiratory or circulatory depression.
💰 Price & brands in your area
🏛️ Official price in Palestine — Ministry of Health price list:
| Product | Company | Pack | Price |
|---|---|---|---|
| PARACOD TABLETS (20 TAB) Paracetamol 325 mgand 20 mg Codeine phosphate | Pharmacare Company | 20 TABLETS / BOX | 19 ₪ |
| ROKACET 20 CAP Paracetamol-Codeine phosphate | Alram Drug Store | 20 CAP | 24 ₪ |
| BRONCHOLATE FORTE SYR.NEW 120 ml pseudoephedrine HCL 20mg diphenhydramine HCL 10mg codeine phosphate 5mg | AL- JAZEERA DRUG STORE | 120 ml | 31 ₪ |
| ROKACET PLUS CAP 24) Paracetamol-Codeine phosphate | Alram Drug Store | 24 CAP | 45 ₪ |
📍 Find the nearest pharmacy
Your location is used only in your browser to show nearby pharmacies — we don't store it.
Open in Google Maps👨⚕️ For healthcare professionals
Mechanism of action
Butalbital is a barbiturate and a GABA A receptor agonist that may inhibit excitatory AMPA receptors. Aspirin is a nonsteroidal anti-inflammatory drug and a non-selective irreversible inhibitor of cyclooxygenases. Caffeine is a methylxanthine and CNS stimulant; its effects may be due to antagonism of adenosine receptors. Codeine is an opioid agonist relatively selective for the mu-opioid receptor but with a much weaker affinity than morphine, and its analgesic properties have been speculated to come from its conversion to morphine.
Labeled dosing
Initiate treatment with one or two capsules every 4 hours as needed for pain, and at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient's response. Total daily dose should not exceed 6 capsules. Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals, and periodically reassess patients for the continued need for opioid analgesics, for signs or symptoms of adverse reactions, and for the development of addiction, abuse, or misuse. Do not rapidly reduce or abruptly discontinue in a physically dependent patient.
- Should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks
- Discuss opioid overdose reversal agents and options for acquiring them with the patient and/or caregiver when initiating and renewing treatment
- Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases
- Reserve concomitant prescribing with benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate
🎓 Key points for students
- The product is a Schedule III controlled substance because it contains codeine
- Butalbital is a barbiturate and codeine is an opioid; both carry risks of addiction and dependence
- Aspirin is a nonsteroidal anti-inflammatory drug and a non-selective irreversible inhibitor of cyclooxygenases
- Caffeine is a methylxanthine and CNS stimulant
- The label's maximum total daily dose is 6 capsules
- Contraindicated in children younger than 12 years and for postoperative management in children younger than 18 years following tonsillectomy and/or adenoidectomy
EME runs your whole clinic: appointments with WhatsApp reminders, patient files, finance & inventory, a patient portal and a members-price medical store — with your data isolated and protected.
Try EME free How we protect your data❓ FAQ
What is this drug used for?
It is indicated for the management of the symptom complex of tension (or muscle contraction) headache when non-opioid analgesics and alternative treatments are inadequate.
Can I adjust the dose myself?
No. The dose is set by the doctor or pharmacist and should be followed without change.
What are the most serious risks?
Addiction, abuse, and misuse, and life-threatening respiratory depression, especially during initiation, following a dosage increase, or with concomitant use of benzodiazepines or other CNS depressants.
Can it be used in children?
It is contraindicated for all children younger than 12 years of age and for postoperative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy.
Can it be used during pregnancy or breastfeeding?
Limit dose and duration between about 20 and 30 weeks of gestation and avoid use at about 30 weeks of gestation and later because of fetal risks. Breastfeeding is not recommended.
What should I do in case of overdose?
Overdose can cause respiratory depression, coma, and death. Priorities include securing the airway, assisted ventilation, and an opioid overdose reversal agent if needed, so seek emergency medical help immediately.
⚕️ For education only — not a substitute for advice from your doctor or pharmacist. Do not start or stop any medicine without advice. Source: official FDA drug label via openFDA (2025-11), simplified. Updated: 2026-11-16.